Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Aramchol Concentrations With Once or Twice Daily Dosing

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03774173
Recruitment Status : Completed
First Posted : December 12, 2018
Last Update Posted : August 9, 2019
Sponsor:
Collaborators:
Hammersmith Medicines Research
Analyst Research Laboratories
Diamond Pharma Services Regulatory Affairs Consultancy
Information provided by (Responsible Party):
Galmed Pharmaceuticals Ltd

Brief Summary:
The trial is an open-label, 2-period, randomised, crossover study of the plasma concentrations of aramchol, in which subjects will receive oral doses of aramchol at 300 mg twice daily and 600 mg once daily.

Condition or disease Intervention/treatment Phase
Healthy Drug: Aramchol Phase 1

Detailed Description:

The trial is an open-label, 2-period, randomised, crossover study of the plasma concentrations of aramchol, in which subjects will receive oral doses of aramchol at 300 mg twice daily (every 12 h) for 9 days in one period, with a single dose in the morning of Day 10, and 600 mg once daily (every 24 h) for 10 days in the other period. A pharmacokinetic profile will be obtained over the dosing interval on Day 10 of each period.

Enrolment of 16 subjects is planned with each subject taking part in the 2 study periods. The subjects will be randomised 1:1 so that 8 subjects receive each regimen in the first period and the alternate regimen in the second period.

Subjects will be screened within 21 days before their first dose of study medicine. In each period they will remain resident on the ward from Day -1 until the morning of Day 11. Subjects will attend a follow-up visit 14 days (±2 days) after the end of the second period. There will be an interval of at least 7 days between Periods 1 and 2.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:

Subjects will receive oral doses of aramchol at 300 mg twice daily (every 12 h) for 9 days in one period, with a single dose in the morning of Day 10, and 600 mg once daily (every 24 h) for 10 days in the other period.

Enrolment of 16 subjects is planned with each subject taking part in the 2 study periods. The subjects will be randomised 1:1 so that 8 subjects receive each regimen in the first period and the alternate regimen in the second period.

Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Randomised, Open-label Study to Compare Plasma Concentrations of Aramchol in Healthy Volunteers After Once or Twice Daily Oral Dosing to Steady State
Actual Study Start Date : December 8, 2018
Actual Primary Completion Date : February 3, 2019
Actual Study Completion Date : March 5, 2019

Arm Intervention/treatment
Experimental: Aramchol 300 mg
Aramchol 300 mg twice daily (every 12 hours)
Drug: Aramchol
One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily

Experimental: Aramchol 600 mg
Aramchol 600 mg once daily (every 24 hours)
Drug: Aramchol
One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily




Primary Outcome Measures :
  1. Pharmacokinetics (PK) of aramchol [ Time Frame: PK parameters will be measured on Days 7, 8 , 9, and 10. ]
    AUC

  2. Pharmacokinetics of aramchol [ Time Frame: PK parameters will be measured on Days 7, 8 , 9, and 10. ]
    Cavg

  3. PK of aramchol [ Time Frame: PK parameters will be measured on Days 7, 8 , 9, and 10. ]
    Ctau

  4. Pharmacokinetics (PK) of aramchol [ Time Frame: K parameters will be measured on Days 7, 8 , 9, and 10. ]
    Tmax


Secondary Outcome Measures :
  1. Vital signs and physical examination [ Time Frame: During both treatment periods vital signs will be assessed on Days 1, 5 and 10. ]
    Systolic and diastolic blood pressure, Heart rate, Oral temperature and Respiratory rate

  2. Electrocardiogram [ Time Frame: During both treatment periods ECG will be assessed on Days 1, 5 and 10. ]
    12-lead ECGs

  3. Laboratory safety tests: Biochemistry [ Time Frame: On Day -1, Day 5,on Day 11. ]
    Usual tests.

  4. Laboratory safety tests: Hematology [ Time Frame: On Day -1, Day 5,on Day 11. ]
    haemoglobin, red blood cells, mean corpuscular volume , mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, haematocrit, white blood cells and platelets.

  5. Laboratory safety tests: Urinalysis [ Time Frame: On Day -1, Day 5,on Day 11. ]
    Usual Dipstick test

  6. Safety and tolerability: Adverse events (AEs). [ Time Frame: From screening visit to 14 days after the last dose in period 2. ]
    Adverse events are collected during entire study period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female healthy volunteer.
  2. Aged 18-45 years at time of consent.
  3. A body mass index (BMI; Quetelet index) in the range 18.0-30.9.
  4. Ability to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.
  5. Willingness to give written consent to participate after reading and understanding the information and consent form, and after having the opportunity to discuss the trial with the investigator or his delegate.
  6. Agree to use effective contraception as described in Section 11.
  7. Agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication.
  8. Willingness to give written consent to have data entered into The Overvolunteering Prevention System (TOPS).

Exclusion Criteria:

  1. Woman who is pregnant or lactating, or pre-menopausal woman who is sexually active and not using a reliable method of contraception (see Section 11).
  2. Of East Asian descent including, but not limited to, Chinese, Japanese, Korean, Mongolian, or Vietnamese.
  3. Smoker, or has smoked cigarettes or other tobacco or nicotine products in the last 12 months.
  4. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the volunteer.
  5. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (AP) >ULN at the screening visit. A repeat is allowed on one occasion for determination of eligibility.
  6. Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer's participation in the trial or make it unnecessarily hazardous.
  7. History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs including gastrointestinal disorder or of oesophageal, gastric, biliary or intestinal surgery (excluding herniotomy and appendectomy).
  8. Use of anticholinergic or other drugs known to affect gastrointestinal motility during the 7 days before the first dose of trial medication.
  9. Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness.
  10. Surgery (eg stomach bypass) or medical condition that might affect absorption of medicines.
  11. Presence or history of severe adverse reaction to any drug or a history of sensitivity to aramchol, cholic acid, bile acid sequestrants, or any excipients in the tablets.
  12. Use of a prescription medicine (except oral contraceptives in females), or any other medicine or herbal remedy (including St John's wort) known to interfere with enzymes in the liver, during the 28 days before the first dose of trial medication; or use of any other over-the-counter medicine, with the exception of acetaminophen (paracetamol), during the 7 days before the first dose of trial medication.
  13. Receipt of an investigational product (including prescription medicines) as part of another clinical trial within the 3 months before first admission to this study; in the follow-up period of another clinical trial at the time of screening for this study.
  14. Presence or history of drug or alcohol abuse, or intake of more than 14 units of alcohol weekly.
  15. Blood pressure and heart rate in supine position at the screening examination outside the ranges: blood pressure 100-140 mm Hg systolic, 50-90 mm Hg diastolic; heart rate 45_90 beats/min, unless judged not clinically significant. Borderline values (ie values that are within 5 mm Hg for blood pressure or 5 beats/min for heart rate) will be repeated. Subjects can be included if the repeat value is within range or still borderline, but deemed not clinically significant by the investigator.
  16. Possibility that the volunteer will not cooperate with the requirements of the protocol.
  17. Evidence of drug abuse on urine testing.
  18. Positive test for hepatitis B, hepatitis C or HIV.
  19. Loss of more than 400 mL blood during the 3 months before the trial, eg as a blood donor.
  20. Objection by GP to volunteer entering trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03774173


Locations
Layout table for location information
United Kingdom
Hammersmith Medicines Research (HMR)
London, United Kingdom, NW10 7EW
Sponsors and Collaborators
Galmed Pharmaceuticals Ltd
Hammersmith Medicines Research
Analyst Research Laboratories
Diamond Pharma Services Regulatory Affairs Consultancy
Investigators
Layout table for investigator information
Principal Investigator: Adeep Puri, M.D. Hammersmith Medicines Research
Layout table for additonal information
Responsible Party: Galmed Pharmaceuticals Ltd
ClinicalTrials.gov Identifier: NCT03774173    
Other Study ID Numbers: Aramchol 017
First Posted: December 12, 2018    Key Record Dates
Last Update Posted: August 9, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes